voruciclib   Click here for help

GtoPdb Ligand ID: 9923

Synonyms: P1446A | P1446A-05
Compound class: Synthetic organic
Comment: Voruciclib (P1446A, or P1446A-05) is an orally active, non-selective CDK inhibitor that was developed for antineoplastic potential. Potent inhibition of CDK9, 4/6 and 1 by voruciclib is considered as a novel pro-apoptotic mechanism applicable to the treatment of malignant melanoma [3] and to overcome resistance to Bcl-2 inhibition (e.g. by venetoclax) in B cell malignancies [2,4].
Use of voruciclib in combination with BRAF inhibitors for the treatment of malignant melanoma is claimed in patent US20160136132A1 [1]. Preparation of pure (+)-trans enantiomer of the compound shown here, is claimed in patent WO2007148158A1 [5].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 3
Hydrogen bond donors 3
Rotatable bonds 4
Topological polar surface area 94.14
Molecular weight 469.09
XLogP 4.88
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES OCC1N(C)CCC1c1c(O)cc(c2c1oc(cc2=O)c1ccc(cc1Cl)C(F)(F)F)O
Isomeric SMILES OC[C@@H]1N(C)CC[C@H]1c1c(O)cc(c2c1oc(cc2=O)c1ccc(cc1Cl)C(F)(F)F)O
InChI InChI=1S/C22H19ClF3NO5/c1-27-5-4-12(14(27)9-28)19-15(29)7-16(30)20-17(31)8-18(32-21(19)20)11-3-2-10(6-13(11)23)22(24,25)26/h2-3,6-8,12,14,28-30H,4-5,9H2,1H3/t12-,14+/m1/s1
No information available.
Summary of Clinical Use Click here for help
Voruciclib (P1446A-05) reached Phase 1 clinical trial, with ClinicalTrials.gov listing two completed studies and two suspended studies (a decision by the sponsor, Piramal Enterprises Limited, which is reportedly not related to patient safety). Click here to link to the full list of P1446A-05 trials at ClinicalTrials.gov.